drugset / Trial / NCT02881138
A Study of RC48-ADC in Subjects With HER2-Positive Advanced Malignant Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
A Phase I Study to Evaluate the Safety,Tolerability and Pharmacokinetics of RC48-ADC for Injection in Subjects With Advanced Malignant Solid Tumors With HER2-positive
Timeline
- Start
- 2016-03-01
- Primary completion
- 2020-04-30
- Completion
- 2020-07-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Disitamab Vedotin | Monoclonal antibody | 0.5 mg/kg | — |
| Subject | Disitamab Vedotin | Monoclonal antibody | 1 mg/kg | — |
| Subject | Disitamab Vedotin | Monoclonal antibody | 1.5 mg/kg | — |
| Subject | Disitamab Vedotin | Monoclonal antibody | 2 mg/kg | — |
| Subject | Disitamab Vedotin | Monoclonal antibody | 2.5 mg/kg | — |